{
  "docId": "019dd923-5ca1-7489-b636-bc879d1b6d64",
  "docSlug": "17680cec2cbd3510",
  "documentTitle": "Accelerated Access Review UK Mapping",
  "authorId": "Deloitte",
  "authorName": "Deloitte",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.333,
  "pageNumber": 14,
  "pageCount": 109,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "initiative_list",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": [
    "headline_text",
    "numbered_list",
    "paragraph"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b636-bc879d1b6d64/14",
  "deckHref": "/decks/019dd923-5ca1-7489-b636-bc879d1b6d64",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b636-bc879d1b6d64.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b636-bc879d1b6d64#slide-14",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Whilst regulatory issues will be considered UK-wide, cost effectiveness and adoption will be examined on an England-only basis",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-ba8c-7422-853b-a2440f0fe706",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.62,
        "w": 0.86,
        "x": 0.07,
        "y": 0.23
      },
      "kind": "list",
      "text": "1. To map the current processes and pathways through which innovative medicines, devices and diagnostics are assessed from proof of concept through regulation, cost-effectiveness assessment and adoption in the UK\n2. To understand how these processes and pathways work in practice\n3. To identify issues, barriers and opportunities within the UK's current approach, and highlight how and when innovation creates the opportunity to evolve the processes and pathways now and in the future\n4. To identify particular areas within current pathways and processes that will be challenged by the new types of product and environment, assess the degree to which the system is future-proofed and identify priority areas for change\n5. To identify the key features which allow rapid development in 'analogous sectors (innovative, high market failure, high upfront costs, large-scale public use), and to explore whether any of these features – or lessons learnt from them – could be effectively mirrored in the development pathways for medicines, devices and diagnostics",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2ab75cbc-3bb2-4bd0-8e4a-48f17d49acf6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.72,
        "x": 0.14,
        "y": 0.88
      },
      "kind": "paragraph",
      "text": "Whilst regulatory issues will be considered UK-wide, cost effectiveness and adoption will be examined on an England-only basis",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7633b09f-3299-4766-b9ee-4db5ab5417d4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.04,
        "y": 0.11
      },
      "kind": "paragraph",
      "text": "There were 5 key aims of workstream 1; these aims are covered in this report with the associated detailed end-to-end pathways created to support workstream 1",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a313a9a1-a090-443d-9441-982fef58f584",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "Workstream 1 objectives",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e6c6a9a-8ae6-4c6c-a66d-a9657038179d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "2f6b84ed-6806-4fb2-9005-f32246b2f2ec",
      "evidence": "1. To map the current processes and pathways through which innovative medicines, devices and diagnostics are assessed from proof of concept through regulation, cost-effectiveness assessment and adoption in",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 10,
      "beatId": "aacd1ccc-bd28-4624-b7f6-626b3a9a4a01",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The document highlights the consequences of not addressing these challenges, such as limited access to new treatments and technologies.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "216c31e8-2aee-4a6b-81ea-25d4d04ac422",
      "evidence": "The document highlights the consequences of not addressing the challenges, such as limited access to new treatments and technologies.",
      "position": 0,
      "objective": "What are the consequences of not improving access to medical innovations?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}